331 related articles for article (PubMed ID: 26783163)
1. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Dahl J; Marx K; Jabbour E
Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
[TBL] [Abstract][Full Text] [Related]
2. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
Kantarjian HM; Su Y; Jabbour EJ; Bhattacharyya H; Yan E; Cappelleri JC; Marks DI
Cancer; 2018 May; 124(10):2151-2160. PubMed ID: 29508899
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
8. Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
Fingrut W; Davis W; McGinnis E; Dallas K; Ramadan K; Merkeley H; Leitch H; Abou Mourad Y; Cassaday RD; Ross C; Léger C
Curr Oncol; 2020 Dec; 28(1):252-259. PubMed ID: 33704192
[TBL] [Abstract][Full Text] [Related]
9. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM; Stock W; Cassaday RD; DeAngelo DJ; Jabbour E; O'Brien SM; Stelljes M; Wang T; Paccagnella ML; Nguyen K; Sleight B; Vandendries E; Neuhof A; Laird AD; Advani AS
Clin Cancer Res; 2021 May; 27(10):2742-2754. PubMed ID: 33602684
[TBL] [Abstract][Full Text] [Related]
10. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
11. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
12. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
Tvito A; Rowe JM
Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Jain N; O'Brien S; Thomas D; Kantarjian H
Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K
Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686
[TBL] [Abstract][Full Text] [Related]
16. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.
Wynne J; Wright D; Stock W
Blood Adv; 2019 Jan; 3(1):96-104. PubMed ID: 30622147
[TBL] [Abstract][Full Text] [Related]
17. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
18. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
19. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
Al-Salama ZT
Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Garrett M; Ruiz-Garcia A; Parivar K; Hee B; Boni J
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):211-222. PubMed ID: 30859374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
